Your browser doesn't support javascript.
loading
How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review.
Hoch, Eva; Niemann, Dominik; von Keller, Rupert; Schneider, Miriam; Friemel, Chris M; Preuss, Ulrich W; Hasan, Alkomiet; Pogarell, Oliver.
Afiliação
  • Hoch E; Cannabinoid Research and Treatment Group, Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nußbaumstr. 7, 80336, Munich, Germany. Eva.Hoch@med.uni-muenchen.de.
  • Niemann D; Cannabinoid Research and Treatment Group, Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nußbaumstr. 7, 80336, Munich, Germany.
  • von Keller R; Cannabinoid Research and Treatment Group, Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nußbaumstr. 7, 80336, Munich, Germany.
  • Schneider M; APOPO, University of Agriculture, Martin-Luther-University, Morogoro, Tanzania.
  • Friemel CM; Cannabinoid Research and Treatment Group, Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nußbaumstr. 7, 80336, Munich, Germany.
  • Preuss UW; Vitos Hospital Psychiatry and Psychotherapy, Department of Psychiatry, Psychotherapy and Psychosomatics, Martin-Luther-University, Halle-Wittenberg, Germany.
  • Hasan A; Cannabinoid Research and Treatment Group, Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nußbaumstr. 7, 80336, Munich, Germany.
  • Pogarell O; Cannabinoid Research and Treatment Group, Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nußbaumstr. 7, 80336, Munich, Germany.
Eur Arch Psychiatry Clin Neurosci ; 269(1): 87-105, 2019 Feb.
Article em En | MEDLINE | ID: mdl-30706168
ABSTRACT
We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006-August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were dementia, cannabis and opioid dependence, psychoses/schizophrenia, general social anxiety, posttraumatic stress disorder, anorexia nervosa, attention-deficit hyperactivity disorder, and Tourette`s disorder. Outcome variables were too heterogeneous to conduct a  meta-analysis. A narrative synthesis method was applied. The study quality was assessed using the risk-of-bias tool and SIGN-checklists. THC- and CBD-based medicines, given as adjunct to pharmaco- and psychotherapy, were associated with improvements of several symptoms of mental disorders, but not with remission. Side effects occurred, but severe adverse effects were mentioned in single cases only. In order to provide reliable treatment recommendations, more and larger RCTs with follow-up assessments, consistent outcome measures and active comparisons are needed.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dronabinol / Canabidiol / Moduladores de Receptores de Canabinoides / Maconha Medicinal / Transtornos Mentais Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dronabinol / Canabidiol / Moduladores de Receptores de Canabinoides / Maconha Medicinal / Transtornos Mentais Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article